Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Mayo who wrote (315)	1/4/1999 9:27:00 PM
From: aknahow	Respond to of 712

We agree and I am being a bit unfair as the info. on collaborations is in the 10K. I just was surprised at the lack of hard data in the annual report. 10K info. The following table summarizes COR's primary programs and product candidates. This table is qualified in its entirety by reference to the more detailed descriptions appearing elsewhere in this Report. <TABLE> <CAPTION> - ------------------------------------------------------------------------------------------------------- SELECTED PROGRAMS PRIMARY AND PRODUCT CANDIDATES STATUS THERAPEUTIC INDICATIONS ---------------------- ------ ----------------------- <S> <C> <C> GP IIB-IIIA INHIBITOR PROGRAM INTEGRILIN(1) Regulatory Review(2) Acute ischemic complications following coronary angioplasty Regulatory Review(2) Unstable angina/non-Q-wave MI Phase II Acute myocardial infarction (ST segment elevation) Oral Phase I Prevention of acute ischemic coronary syndromes and stroke FACTOR XA INHIBITOR PROGRAM Parenteral/Subcutaneous Preclinical Development Prevention and treatment of venous thromboembolism Oral Research Prevention and treatment of venous thromboembolism GROWTH FACTOR AND RECEPTOR ANTAGONIST PROGRAM(3) Parenteral Preclinical Development Restenosis; prevention of neo- vascularization, e.g., diabetic retinopathy Oral Research Restenosis; prevention of neo- vascularization, e.g., diabetic retinopathy THROMBIN RECEPTOR INHIBITOR PROGRAM(4) Research Acute and chronic ischemic coronary syndromes, restenosis and stroke prevention PLATELET ADP RECEPTOR PROGRAM Research Acute and chronic ischemic coronary syndromes, restenosis and stroke prevention MYOCARDIAL SIGNAL Research Congestive heart failure; ischemic coronary TRANSDUCTION PROGRAM disease INTEGRIN SIGNALING PROGRAM Research Multiple </TABLE> (1) INTEGRILIN is subject to a collaborative agreement with Schering Corporation and Schering-Plough Corporation. See "Collaborative Agreements - Relationship with Schering." (2) In January 1998, the FDA's Cardiovascular and Renal Drugs Advisory Panel met and recommended INTEGRILIN for marketing approval for use in the setting of coronary angioplasty. See "Arterial Thrombosis - INTEGRILIN product candidate." (3) This program is being pursued in collaboration with Kyowa Hakko Kogyo Co., Inc. See "Collaboration Agreements - Relationship with Kyowa Hakko." (4) This program is being pursued in collaboration with Ortho Pharmaceutical Corporation. See "Collaboration Agreements - Relationship with Ortho."

To: Robert Mayo who wrote (315)	1/6/1999 11:43:00 PM
From: aknahow	Respond to of 712

Patent issued yesterday. (1 of 28) United States Patent 5,856,448 Coughlin Jan. 5, 1999 Antibodies specifically reactive with thrombin receptor and its components Abstract The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.